DE19529085A1 - Nail lacquer to control scale formation round nail - contg glucocorticoid, cyclosporin and/or calcipotriol - Google Patents

Nail lacquer to control scale formation round nail - contg glucocorticoid, cyclosporin and/or calcipotriol

Info

Publication number
DE19529085A1
DE19529085A1 DE1995129085 DE19529085A DE19529085A1 DE 19529085 A1 DE19529085 A1 DE 19529085A1 DE 1995129085 DE1995129085 DE 1995129085 DE 19529085 A DE19529085 A DE 19529085A DE 19529085 A1 DE19529085 A1 DE 19529085A1
Authority
DE
Germany
Prior art keywords
nail
calcipotriol
cyclosporin
glucocorticoid
nail polish
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE1995129085
Other languages
German (de)
Inventor
Christiane Dr Med Wurdel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to DE1995129085 priority Critical patent/DE19529085A1/en
Publication of DE19529085A1 publication Critical patent/DE19529085A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/345—Alcohols containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q3/00—Manicure or pedicure preparations
    • A61Q3/02—Nail coatings

Abstract

A nail lacquer to combat scale formation in the nail region is claimed. The lacquer contains fluorinated glucocorticoid (Ia), cyclosporin (Ib) and calcipotriol (Ic) alone or in a combination of defined proportions.

Description

Die Erfindung betrifft einen Nagellack zur Bekämpfung der Schuppenflechte im Nagelbereich.The invention relates to a nail polish for combating Psoriasis in the nail area.

Bekannt ist die Behandlung von Nagelmykosen, insbes. im distalen Bereich, mit "Loceryl"® Nagellack Roche mit einem Befall unter 80% der Nageloberfläche.The treatment of nail mycoses is known, especially in the distal Area covered with "Loceryl" ® nail polish Roche with an infestation below 80% of the nail surface.

Weiter ist die Behandlung von Pilzerkrankungen der Nägel mittels Nagel Batrafen ® (Rp) bekannt.Next is the treatment of fungal diseases of the nails Nagel Batrafen ® (Rp) known.

Im Schrifttum wird weiter über Erfolge lokaler Therapie mit einer 10%igen öligen Cyclosporinlösung sowie gutes Ansprechen schwerer Nagelpsoriasis auf systematische Cyclosporingaben berichtet. Weiter ist Calcipotriol als effektives, topisches Antipsoriatikum dargestellt worden. In einer Kombinationstherapie haben sich Cyclopsorin und Calcipotriol bewährt (NEWS-LETTER 1/1995, Sönnichsen, N.; Friedmann, D.; Schering AG, GB Deutschland, Berlin).The literature continues to talk about the success of local therapy a 10% oily cyclosporin solution and good response severe nail psoriasis on systematic cyclosporin doses reported. Calcipotriol is also an effective, topical Antipsoriatic has been shown. In a Combination therapy has cyclopsorin and calcipotriol proven (NEWS-LETTER 1/1995, Sönnichsen, N .; Friedmann, D .; Schering AG, GB Germany, Berlin).

Die Behandlungsmethoden mit den vorliegenden Präparaten haben den Nachteil, daß sie nur bei systematischer Gabe (Cyclosporin) die Nagelveränderungen effektiv behandeln bzw. Calcipotriol den Psoriasisnagel nicht erreicht.The methods of treatment with the available preparations have the disadvantage that it can only be administered systematically (cyclosporin) treat the nail changes effectively or calcipotriol Psoriasis nail not reached.

Der im Patentanspruch 1 angegebenen Erfindung liegt das Problem zugrunde, einen Nagellack zur Bekämpfung der Schuppenflechte im Nagelbereich bereitzustellen, der einen wirksamen therapeutischen Effekt besitzt und patientenfreundlich verwendet werden kann.The invention specified in claim 1 is the problem based on a nail polish to fight psoriasis in the To provide nail area that is an effective therapeutic Has effect and can be used patient-friendly can.

Erfindungsgemäß wird das Problem dadurch gelöst, daß fluorierte Glukokortikoide, Cylcpsorin und Calcipotriol einzeln oder in Kombination in dem in den Patentansprüchen definierbaren Verhältnis in den Nagellack eingearbeitet sind.According to the invention the problem is solved in that fluorinated Glucocorticoids, Cylcpsorin and Calcipotriol individually or in Combination in the definable in the claims Ratio are incorporated into the nail polish.

Der Vorteil der Erfindung besteht in einer patientenfreundlichen Behandlung der Schuppenflechte im Nagelbereich. Ein weiterer Vorteil der Erfindung besteht in der sauberen und schmerzfreien Anwendung, die auch unter ambulanten Bedingungen einfach durchgeführt werden kann.The advantage of the invention is that it is patient-friendly Treatment of psoriasis in the nail area. Another The advantage of the invention is that it is clean and painless Application that is easy even under outpatient conditions can be carried out.

Die Erfindung wird anhand von drei Ausführungsbeispielen näher erläutert.The invention is illustrated by three exemplary embodiments explained.

Beispiel 1example 1

In 1 g Nagellack sind 0,5 bis 30 mg fluorierte Glukokortikoide eingearbeitet sind.0.5 g to 30 mg fluorinated glucocorticoids are contained in 1 g nail polish are incorporated.

Beispiel 2Example 2

In 1 g Nagellack sind 0,05 bis 1,25 mg Cyclosporin eingearbeitet sind.0.05 to 1.25 mg of cyclosporin are incorporated into 1 g of nail polish are.

Beispiel 3Example 3

In 1 g Nagellack sind 0,4 bis 3,2 mg Calcipotriol eingearbeitet sind.0.4 to 3.2 mg calcipotriol are incorporated into 1 g nail polish are.

Claims (4)

1. Nagellack zur Bekämpfung der Schuppenflechte im Nagelbereich, dadurch gekennzeichnet, daß fluorierte Glukokortikoide, Cylcpsorin und Calcipotriol einzeln oder in Kombination in einem definierbaren Verhältnis in den Nagellack eingearbeitet sind.1. nail polish for combating psoriasis in the nail area, characterized in that fluorinated glucocorticoids, cylcpsorin and calcipotriol are incorporated individually or in combination in a definable ratio in the nail polish. 2. Nagellack nach Anspruch 1, dadurch gekennzeichnet, daß in 1 g Nagellack 0,5 bis 30 mg fluorierte Glukokortikoide eingearbeitet sind.2. Nail polish according to claim 1, characterized in that in 1 g nail polish 0.5 to 30 mg fluorinated glucocorticoids are incorporated. 3. Nagellack nach Anspruch 1, dadurch gekennzeichnet, daß in 1 g Nagellack 0,05 bis 1,25 mg Cyclosporin eingearbeitet sind.3. Nail polish according to claim 1, characterized in that in 1 g of nail polish 0.05 to 1.25 mg of cyclosporin are incorporated. 4. Nagellack nach Anspruch 1, dadurch gekennzeichnet, daß in 1 g Nagellack 0,4 bis 3,2 mg Calcipotriol eingearbeitet sind.4. nail polish according to claim 1, characterized in that in 1 g nail polish 0.4 to 3.2 mg calcipotriol are incorporated.
DE1995129085 1995-08-08 1995-08-08 Nail lacquer to control scale formation round nail - contg glucocorticoid, cyclosporin and/or calcipotriol Withdrawn DE19529085A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE1995129085 DE19529085A1 (en) 1995-08-08 1995-08-08 Nail lacquer to control scale formation round nail - contg glucocorticoid, cyclosporin and/or calcipotriol

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE1995129085 DE19529085A1 (en) 1995-08-08 1995-08-08 Nail lacquer to control scale formation round nail - contg glucocorticoid, cyclosporin and/or calcipotriol

Publications (1)

Publication Number Publication Date
DE19529085A1 true DE19529085A1 (en) 1997-02-13

Family

ID=7768957

Family Applications (1)

Application Number Title Priority Date Filing Date
DE1995129085 Withdrawn DE19529085A1 (en) 1995-08-08 1995-08-08 Nail lacquer to control scale formation round nail - contg glucocorticoid, cyclosporin and/or calcipotriol

Country Status (1)

Country Link
DE (1) DE19529085A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0913154A1 (en) * 1997-08-21 1999-05-06 Hoechst Marion Roussel Deutschland GmbH Antipsoriatic nail lacquer
WO2010080913A1 (en) * 2009-01-08 2010-07-15 Allergan, Inc. Cyclosporine compositions for enhancing nail growth

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0913154A1 (en) * 1997-08-21 1999-05-06 Hoechst Marion Roussel Deutschland GmbH Antipsoriatic nail lacquer
AU740615B2 (en) * 1997-08-21 2001-11-08 Aventis Pharma Deutschland Gmbh Antipsoriatic nail polish
US6352686B2 (en) 1997-08-21 2002-03-05 Aventis Pharma Deutschland Gmbh Antipsoriatic nail polish
WO2010080913A1 (en) * 2009-01-08 2010-07-15 Allergan, Inc. Cyclosporine compositions for enhancing nail growth
US9101550B2 (en) 2009-01-08 2015-08-11 Allergan, Inc. Compositions for enhancing nail growth

Similar Documents

Publication Publication Date Title
DE3528979C2 (en)
DE2046119C2 (en) Means for treating acne
DE60219478T2 (en) ORAL GIVEN OF 6-HYDROXY-OXYMORPHONE AS ANALGETIC
EP0448961A2 (en) Nitroglycerine pumpspray
US5866143A (en) Topical application of opioid drugs such as morphine for relief of itching and skin disease
DE3246081A1 (en) Nitroglycerin spray
DE19737348C2 (en) Pharmaceutical composition containing clindamycin and clotrimazole
DE3940389A1 (en) Therapeutical compsn. comprising gas, e.g. oxygen dissolved in liq. - for immuno-stimulation in cancer therapy, reviving accident victims and improving oxygen transport in vascular coronary diseases
DE19529085A1 (en) Nail lacquer to control scale formation round nail - contg glucocorticoid, cyclosporin and/or calcipotriol
US5962512A (en) Oil containing 5-methoxypsoralen at a concentration of 60-100 ppm, and its use in treatment of psoriasis
DE2658984C2 (en) Injectable insulin preparations
DE2606516C2 (en)
DE3830333C1 (en) Pharmaceutical composition for the treatment of the eruption caused by herpes viruses
DE60024408T2 (en) USE OF TRICYCLIC ANTIDEPRESSIVA FOR THE TREATMENT OF HEADACHE
EP0265662A2 (en) Pharmaceutic composition
EP0033164A2 (en) Composition for preventing and inhibiting baldness
EP0211093B1 (en) Medicine for the treatment of herpes
DE10238161A1 (en) Mucosal or topical administration of minerals, e.g. for treating muscle spasms, psoriasis or osteoporosis or promoting wound healing, comprises direct application of mineral solution from ampoule
DE10230558B4 (en) Medical kit for administration in a combination therapy
DE3605570C1 (en) Composition for tightening areas of human skin
EP0744177A2 (en) Composition containing at least one essential oil and a provitamin, useful in the prevention and treatment of pressure sores
EP0388417B1 (en) Hair growth promoter
DE2134899A1 (en) DEVICES FOR INHALATION THERAPY OF BRONCHIAL DISEASES
DE3834961C2 (en)
DE19603477A1 (en) Agent for treatment of tumours

Legal Events

Date Code Title Description
8139 Disposal/non-payment of the annual fee